Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2022 - 12 - 10 crawled time : 20:20 save search
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Adds to Robust IMBRUVICA® (ibrutinib) Science
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
| Email alert
Add to watchlist
FNCTF | News | $11.0354 -20.84% 320
|
Communications
| Email alert
Add to watchlist
imbruvica meeting
Janssen Presents New Data for Talquetamab, a First-in-Class GPRC5DxCD3 Bispecific Antibody, Suggesting Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
| Email alert
Add to watchlist
MEDIAWAN AND PLAN B ENTERTAINMENT JOIN FORCES TO CREATE GLOBAL PRODUCTION PLATFORM
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
MC | News | $51.26 0.29% 0.0% 310K
|
Finance
| Email alert
Add to watchlist
KKR | $94.63 -1.72% -1.93% 2.3M
|
Finance
| Email alert
Add to watchlist
BNPQY | News 6 d | $34.08 -2.68% 500K
|
Finance and Insurance
| Email alert
Add to watchlist
BNPQF | News 6 d | $67.96 -13.4% 400
|
Finance
| Email alert
Add to watchlist
global platform
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI™ (teclistamab-cqyv) in Combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
| Email alert
Add to watchlist
faspro darzalex trial
AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting for Investigational Navitoclax in Combination With Ruxolitinib for JAK Inhibitor-Naïve Myelofibrosis Patients
Published: 2022-12-10 (Crawled : 20:20) - prnewswire.com
ABBV | $164.25 1.05% -0.76% 4M
|
Health Technology
| Email alert
Add to watchlist
meeting
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
ARGX | $366.37 -1.16% -1.18% 270K
|
Health Technology
| Email alert
Add to watchlist
vyvgart treatment trial potential
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
AFMD | News | $5.26 -2.05% -2.09% 33K
|
Health Technology
| Email alert
Add to watchlist
afm13 meeting study phase 1
Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
FATE | $5.28 -1.86% -1.89% 2.1M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $144.77 0.22% -0.01% 9.3M
|
Health Technology
| Email alert
Add to watchlist
meeting therapeutics
Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
AFMD | News | $5.26 -2.05% -2.09% 33K
|
Health Technology
| Email alert
Add to watchlist
afm13 topline study
Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASH 2022
Published: 2022-12-10 (Crawled : 20:20) - globenewswire.com
ONCT P | $8.71 0.23% 0.23% 4K
|
Health Technology
| Email alert
Add to watchlist
therapeutics
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.